Bioventix logo

BVXP - Bioventix News Story

4145p 30.0  0.7%

Last Trade - 09/04/21

Small Cap
Market Cap £215.9m
Enterprise Value £210.1m
Revenue £10.2m
Position in Universe 810th / 1817

Bioventix Plc: Result of AGM

Thu 10th December, 2020 3:03pm
Bioventix plc

(“Bioventix” or the “Company”)

Result of AGM

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting
(“AGM”), all resolutions put to shareholders were duly passed.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix ( specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.